The World Health Organization is tracking a new strain of Covid-19 called EG.5 or Eris
The World Health Organization is tracking a new strain of Covid-19 called EG.5 or Eris, which is responsible for a growing proportion of cases in countries including China and the US.
The World Health Organization has classified it as a “problem type,” meaning it will be monitored for mutations that could make it more serious.
Based on current data, the World Health Organization states that this poses a low public health risk at the global level, in line with other variables currently in use. And in May, the World Health Organization said more broadly that “Covid-19” is now “an ongoing and ongoing health problem that no longer constitutes a public health emergency of international concern,” according to CNBC seen by Al Arabia. net.
Symptoms and Their Prevalence
The symptoms of “Eris” are reported to be similar to previous variants, including fever, cough, sore throat, fatigue, runny nose, and changes in taste and smell.
“While EG.5 has shown increased proliferation, growth advantage, and immune evasion characteristics, no change in disease severity has been documented to date,” according to a WHO risk assessment published on Aug. 9.
She added that these characteristics could cause the variable to become dominant in some countries or even the world.
The official name of the variant is EG.5, and “Eris” is a random nickname given out on the internet that later popularized the “EG.5.1” variant.
Based on sequencing information provided to the Global Initiative to Share All Influenza Data (GISAID) as of August 7, the bulk of EG.5 infections have been identified in China, followed by the US, South Korea, Japan, and Canada.
It has also been found in Australia, Singapore, UK, France, Portugal and Spain.
EG.5 is currently the dominant strain in the United States, accounting for 17.3% of cases as of the week ending August 5, according to the Centers for Disease Control and Prevention.
Vaccine Reformulation
This happens at a time when companies are getting ready; Moderna, Pfizer and Novavax will launch new Covid vaccines this fall that target XBB variants that evolved from the Corona omicron variant.
Novavax stated that its vaccine “stimulates functional immune responses to XBB sub-variants, including XBB.1.5, XBB.1.16 and XBB.2.3.”
“EG.5” is a strain derived from a variant that has the same high amino acid profile as “XBB.1.5”.
For his part, Justin Lessler, professor of epidemiology at UNC Gillings School of Global Public Health, said: “EG.5 is part of the XBB strain and is more closely related to XBB variants than to previous vaccine strains.”
“For this reason, the reformulated vaccines that will be available this fall are expected to provide better protection against EG.5 than previous vaccines.”
The new vaccines are expected to be available in the United States from the end of September, according to CDC director Mandy Cohen, as responsibility for distributing vaccines shifts to the private sector.
